Newsletter | November 19, 2026

11.19.26 -- OPCU: Strengthening Large Molecule Programs From Manufacturing To Fill-Finish

 

 

Moving a large-molecule therapy toward commercialization requires more than scaling a manufacturing process. Formulation, technology transfer, capacity, supply continuity, and sterile fill-finish must work together to protect product quality and keep increasingly complex programs moving forward.

 

Making these decisions earlier can help sponsors identify potential bottlenecks, establish more robust processes, and better prepare for the transition from clinical to commercial supply. In this edition of the Outsourced Pharma Capabilities Update (OPCU), hear from CDMOs addressing key considerations across large molecule manufacturing and fill-finish, from process development and technology transfer to aseptic operations and scale-up. Watch the presentations below for perspectives on building a manufacturing strategy that can adapt as your program advances.

 

Recent Sessions Available On-Demand                                
 AI Drug Manufacturing & Viral Vectors – October 2026                            
 mRNA & Packaging, Labeling & Logistics – October 2026                            
 Fill/Finish – October 2026                            
 ADC – October 2026                        

 

Upcoming OPCU Topics & Times              
 Enabling ADC Success | 12/1/2026, PM Session                              
 Mastering Aseptic Fill-Finish | 12/1/2026, PM Session                          

 

Access more on-demand OPCU recordings and upcoming sessions here.

FILL/FINISH

Thermo Fisher Scientific

Learn how to balance technical, regulatory, and supply chain considerations while avoiding costly late-stage changes and preparing for successful technology transfer, scale-up, and commercialization.

Request Information

Thermo Fisher Scientific

Lonza

Bastian Klöfer, Director of Commercial Development, Drug Product Services, explores Lonza's end-to-end biologics network, spanning drug substance, drug product development, manufacturing, analytics and regulatory support.

Request Information

Lonza

Simtra Biopharma Solutions

Explore new sterile manufacturing capacity for pre-filled syringes, lyophilized vials, and potent therapies, supporting flexibility, scale, and supply resilience.

Request Information

Simtra BioPharma Solutions

PCI Pharma Services

PCI integrates scalable manufacturing, packaging, device assembly, and global regulatory expertise to streamline tech transfer and strengthen supply chain resilience.

Request Information

PCI Pharma Services

Alcami

Discover critical considerations for sterile fill-finish, including manufacturability, scale-up, contamination control, and the path from clinical to commercial supply.

Request Information

Alcami

LARGE MOLECULE

Lonza

Ben Neunstoecklin, Director of Commercial Development, provides an overview of biologics drug substance manufacturing capabilities and global network capacity that supports customer programs from development through commercial supply.

Request Information

Lonza

Cytovance Biologics

Move biologics from research and development toward commercialization with integrated development, analytics, scalable GMP manufacturing, and early-phase fill-finish capabilities.

Request Information

Cytovance Biologics

Novartis Contract Manufacturing

Reliable biologics manufacturing starts with experienced teams, proven tech transfer, and global capacity that scales from clinic to commercial.

Request Information

Novartis Contract Manufacturing

Coriolis Pharma

Integrated drug product development helps biopharma teams identify risks early, optimize formulation and manufacturing, and create stable, scalable biologics ready for clinical and commercial success.

Request Information

Coriolis Pharma

3PBIOVIAN

Integrated CDMO services for biologics and advanced therapies, offering plasmid DNA, viral vectors, fill-finish, and scalable manufacturing from development through commercialization.

Request Information

3PBIOVIAN